Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theriva Biologics ( (TOVX) ) has issued an update.
Theriva Biologics has announced that the European Commission granted orphan medicinal product designation to its leading candidate VCN-01 for treating retinoblastoma, highlighting the urgent need for new therapies. This designation, following similar recognition by the FDA, underscores VCN-01’s potential to transform treatment options, offering significant benefits to patients by enhancing chemotherapy effectiveness and improving immune response against tumors.
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.
